N/A
Manufactured by Boehringer Ingelheim Pharmaceuticals, Inc.
25,050 FDA adverse event reports analyzed
Last updated: 2026-04-14
TIOTROPIUM BROMIDE INHALATION SPRAY is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Boehringer Ingelheim Pharmaceuticals, Inc.. The most commonly reported adverse reactions for TIOTROPIUM BROMIDE INHALATION SPRAY include DYSPNOEA, ASTHMA, COUGH, WHEEZING, PNEUMONIA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for TIOTROPIUM BROMIDE INHALATION SPRAY.
Out of 10,369 classified reports for TIOTROPIUM BROMIDE INHALATION SPRAY:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 25,050 FDA FAERS reports that mention TIOTROPIUM BROMIDE INHALATION SPRAY. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DYSPNOEA, ASTHMA, COUGH, WHEEZING, PNEUMONIA, DRUG INEFFECTIVE. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Boehringer Ingelheim Pharmaceuticals, Inc. in connection with TIOTROPIUM BROMIDE INHALATION SPRAY. Always verify the specific product and NDC with your pharmacist.